CA2480050A1 - Tenascin-w compositions and uses thereof - Google Patents

Tenascin-w compositions and uses thereof Download PDF

Info

Publication number
CA2480050A1
CA2480050A1 CA002480050A CA2480050A CA2480050A1 CA 2480050 A1 CA2480050 A1 CA 2480050A1 CA 002480050 A CA002480050 A CA 002480050A CA 2480050 A CA2480050 A CA 2480050A CA 2480050 A1 CA2480050 A1 CA 2480050A1
Authority
CA
Canada
Prior art keywords
tenascin
val
thr
gly
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002480050A
Other languages
English (en)
French (fr)
Inventor
Ruth Chiquet-Ehrismann
Arnaud Scherberich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2480050A1 publication Critical patent/CA2480050A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA002480050A 2002-03-27 2003-03-26 Tenascin-w compositions and uses thereof Abandoned CA2480050A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0207224.7 2002-03-27
GBGB0207224.7A GB0207224D0 (en) 2002-03-27 2002-03-27 Tenascin-W compositions and uses thereof
PCT/EP2003/003150 WO2003080663A2 (en) 2002-03-27 2003-03-26 Tenascin-w compositions and uses thereof

Publications (1)

Publication Number Publication Date
CA2480050A1 true CA2480050A1 (en) 2003-10-02

Family

ID=9933815

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002480050A Abandoned CA2480050A1 (en) 2002-03-27 2003-03-26 Tenascin-w compositions and uses thereof

Country Status (7)

Country Link
US (2) US7683159B2 (enExample)
EP (1) EP1490400A2 (enExample)
JP (1) JP4469180B2 (enExample)
AU (1) AU2003215673A1 (enExample)
CA (1) CA2480050A1 (enExample)
GB (1) GB0207224D0 (enExample)
WO (1) WO2003080663A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL160507A0 (en) * 2001-08-24 2004-07-25 Advanced Cell Tech Inc Screening assays for identifying differentiation-inducing agents and production of differentiated cells for cell therapy
WO2009053354A1 (en) * 2007-10-22 2009-04-30 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Use of tenascin-w as a biomarker for colon cancer
EP2241323A1 (en) * 2009-04-14 2010-10-20 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Tenascin-W and brain cancers
GB201413357D0 (en) * 2014-07-28 2014-09-10 Philogen Spa Antibodies for treatment and diagnosis
CA3068688A1 (en) * 2017-06-30 2019-01-03 National Institutes Of Biomedical Innovation, Health And Nutrition Biomarker for detecting colorectal cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992004464A2 (en) 1990-09-05 1992-03-19 The Wistar Institute Monoclonal antibodies against tenascin
WO1994021293A1 (en) 1993-03-19 1994-09-29 Duke University Method of treatment of tumors with an antibody binding to tenascin
US6124260A (en) 1998-09-30 2000-09-26 Cedars-Sinai Medical Center Inhibition of smooth muscle cell migration by Tenascin-C peptides
AU2001238585A1 (en) * 2000-02-24 2001-09-03 Human Genome Sciences, Inc. Human polynucleotides, polypeptides, and antibodies
US20030022255A1 (en) 2000-12-22 2003-01-30 Morris David W. Novel compositions and methods for breast cancer
US7892730B2 (en) * 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer

Also Published As

Publication number Publication date
US7683159B2 (en) 2010-03-23
AU2003215673A1 (en) 2003-10-08
JP4469180B2 (ja) 2010-05-26
WO2003080663A2 (en) 2003-10-02
JP2006504397A (ja) 2006-02-09
US20050202430A1 (en) 2005-09-15
WO2003080663A3 (en) 2004-04-01
GB0207224D0 (en) 2002-05-08
US20100173314A1 (en) 2010-07-08
EP1490400A2 (en) 2004-12-29

Similar Documents

Publication Publication Date Title
JP3275024B2 (ja) 血管内皮増殖因子−b
JP4124815B2 (ja) TGF−β型受容体cDNAおよびその用途
EP2167542B1 (en) Neutralizing monoclonal antibody against human dll4
CN101389958B (zh) 使用轴突导向因子netrin-1的活性筛选抗癌化合物的方法
CN105349618B (zh) 三阴性乳腺癌标记物及其在诊断和治疗中的应用
KR101560843B1 (ko) 페리오스틴의 Exon-17 부위에 의해 코드되는 펩티드에 대한 항체를 함유하는 암 치료제
AU2021225180A1 (en) Methods for identification, assessment, prevention, and treatment of metabolic disorders using Slit2
US20040259781A1 (en) Anti-tumour agents and methods of identifying anti-tumour agents
US20100173314A1 (en) Diagnostic methods using tenascin-w compositions
WO1998025946A1 (en) Monoclonal antibodies specific to endothelial cell cadherins and uses thereof
CA2635849A1 (en) An antibody against periostin, and a pharmaceutical composition comprising it for preventing or treating a disease in which periostin is involved
US20210079099A1 (en) Antibody against alpha-11 integrin and its use
AU2011249750B2 (en) Antagonists of Sema3E/PlexinD1 interaction as anti-cancer agents
AU2005211764A1 (en) Inhibiting CAV3 isoforms and the delta25B splice varients for the diagnosis and treatment of cancer
CN111378040B (zh) 检测多种恶性肿瘤细胞的抗体及其应用
KR101008314B1 (ko) Cd9이 과발현된 고형암의 항암제 개발을 위한표적단백질로서의 cd9의 용도
JPH10502252A (ja) Dp−1及びその他のdpタンパク質の阻害剤のアッセイ
JP6281979B2 (ja) 新規インテグリンα9β1リガンドおよびその利用
US6180760B1 (en) Actin filament-binding protein “l-Afadin”
JP2006504397A5 (enExample)
KR102268041B1 (ko) 구강암의 예후 예측용 조성물
US11136368B2 (en) Cancer treatment using CX26 blocking peptides
AU2007203155B2 (en) Human toll homologues
US20030103975A1 (en) Modulation of angiogenesis and endothelialization
Meghnani RAGE (Receptor for Advanced Glycation End Products) in melanoma progression

Legal Events

Date Code Title Description
FZDE Discontinued